NCT04751604View on ClinicalTrials.gov

Improvement of the Nutritional Status Regarding Nicotinamide (Vitamin B3) and the Disease Course of COVID-19

NACompletedINTERVENTIONAL
Enrollment

900

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

July 27, 2022

Study Completion Date

October 20, 2022

Conditions
COVID-19
Interventions
DIETARY_SUPPLEMENT

Nicotinamide

Daily oral administration of 1,000 mg nicotinamide \[1x 500-mg conventional nicotinamide tablet and 1x 500-mg tablet with controlled-ileocolonic-release nicotinamide (CICR-NAM)\] for 4 weeks

DIETARY_SUPPLEMENT

Placebo

Daily oral administration of 2 matching placebo tablets for 4 weeks

Trial Locations (1)

24105

University Hospital Schleswig-Holstein, Kiel

All Listed Sponsors
lead

University Hospital Schleswig-Holstein

OTHER

NCT04751604 - Improvement of the Nutritional Status Regarding Nicotinamide (Vitamin B3) and the Disease Course of COVID-19 | Biotech Hunter | Biotech Hunter